Search

Approximately 300 million people worldwide were living with chronic hepatitis B virus infection as of 2016, however, this number does not account for those who might be living with occult hepatitis B virus infection due to difficulty diagnosing this condition. The multiple genotypes and the ability of the hepatitis B virus to acquire mutations that down-regulate its expression make occult hepatitis B virus infection a very elusive diagnosis. This is especially worrisome when there is a need to start immunosuppressive therapies, since there is a risk of reactivation in undiagnosed patients. We present a case of female patient who was referred to the consultation because she was about to start chemotherapy with an anti-CD20 agent and had a positive anti-HBc and anti-HBs. During routine workup an occult hepatitis B virus infection was diagnosed. Upon further study mutations in the PreCore and Basal Core Promoter regions were identified, as well as, a double genotype D/C. Therapy with tenofovir was initiated before the patient was started on chemotherapy. This case highlights the importance of comprehensive studying of patients who present with apparently resolved chronic hepatitis B virus infection, especially when they are about to start immunosuppressive therapies., (© 2019 The Author(s).)

Protozoal infections that are efficiently transmitted by blood transfusion include Malaria, Chagas Disease, African Trypanosomiasis, Leshmaniasis, Toxoplasmosis and Babesiosis. With exception of Toxoplasmosis and Leishmaniasis, these diseases are endemic in mainly tropical low income countries and, in non-endemic countries like Portugal, the reported cases are imported from these endemic areas by travelers or immigrants. Globalization, with increasing travel and immigration poses the risk of exposition to these infectious agents and raises the issue of possible transmission by blood transfusion. According to recommendations of the Council of Europe, strategies to prevent the transmission of these infections by blood transfusion have been implemented. Given that the risk is introduced by a specific group of donors, travelers or immigrants from endemic areas, the main strategy to prevent this transmission depends on the identification of these groups of donors using questionnaires during the pre-donation procedures. Additional measures, like serological testing and pathogen inactivation procedures, when available, contribute not only to reduce the risk of transmission but also to avoid unnecessary rejections.